Clinical trials: Tremelimumab
Mesothelioma
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.
- Trial name
- NCT05932199
- Testing
- Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Mesothelioma
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
The objective of this study is to determine whether MEDI4736 or combination therapy with MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral immunologic environment in subjects undergoing…
- Trial name
- NCT02592551
- Testing
- MEDI4736, Tremelimumab, no other name
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Hepatocellular Carcinoma
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma.
- Trial name
- NCT06364007
- Testing
- HAIC+STRIDE+Len
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University